Chinese Ostomy Collaboration Group (COCG) Clinical Study -SITI Classification
Condition(s) studied
Investigational drug(s) / intervention(s)
Novel severity grading system of stoma-related complication in cancer patients: Over 5000 stoma patients treated at 26 centers between 2022 and 2023 were classified according to SITI-CD Classification.
Study summary
Colorectal cancer is an important cancer worldwide, and its incidence is increasing year by year. A large proportion of patients may require diverting stoma or even permanent stoma after surgery. Some of these patients will have a variety of stoma-related complications, which seriously affect the quality of life of patients. At present, the mainstream postoperative complication classification is the traditional CD classification, which is suitable for the classification of most postoperative complications. However, due to the unique anatomical characteristics of patients with stoma, the current CD classification system may not be suitable for the classification of patients with stoma-related complications. Therefore, we plan to establish a registry database of colorectal cancer patients with stoma, explore the attribution and incidence of stoma-related complications, and propose a new improved classification system, the SITI classification, on the existing CD classification, for verification and promotion.
Eligibility
Primary outcome measure(s)
- Incidence of stoma complications in different SITI grades — 1year
To understand the complications of different SITI grades, to clarify the rationality and feasibility of SITI grades, and to provide reasonable treatment for patients.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Beijing Cancer Hospital | Beijing | Beijing Municipality |
More Peking University Cancer Hospital & Institute trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07111429 on ClinicalTrials.gov ↗ ← All trials in China